Mercedes Corina Becerra, Sc.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis, Multidrug-Resistant | 50 | 2020 | 938 | 5.840 |
Why?
|
Antitubercular Agents | 45 | 2022 | 1390 | 3.490 |
Why?
|
Tuberculosis | 34 | 2024 | 2030 | 3.140 |
Why?
|
Tuberculosis, Pulmonary | 20 | 2023 | 846 | 2.170 |
Why?
|
Peru | 46 | 2024 | 894 | 2.170 |
Why?
|
Mycobacterium tuberculosis | 30 | 2024 | 1931 | 2.000 |
Why?
|
Contact Tracing | 12 | 2020 | 275 | 1.880 |
Why?
|
Isoniazid | 13 | 2022 | 288 | 1.770 |
Why?
|
Family Characteristics | 12 | 2020 | 1002 | 1.090 |
Why?
|
Drug Resistance, Multiple, Bacterial | 9 | 2016 | 590 | 0.830 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 3 | 2013 | 86 | 0.780 |
Why?
|
Directly Observed Therapy | 6 | 2012 | 139 | 0.710 |
Why?
|
Sputum | 11 | 2021 | 511 | 0.580 |
Why?
|
Rifampin | 6 | 2021 | 345 | 0.470 |
Why?
|
Tuberculosis, Meningeal | 1 | 2014 | 49 | 0.450 |
Why?
|
Medication Systems, Hospital | 1 | 2013 | 154 | 0.400 |
Why?
|
Child, Preschool | 29 | 2022 | 42623 | 0.350 |
Why?
|
Latent Tuberculosis | 3 | 2021 | 224 | 0.350 |
Why?
|
Remote Consultation | 1 | 2013 | 242 | 0.340 |
Why?
|
Adolescent | 38 | 2024 | 89168 | 0.330 |
Why?
|
Microbial Sensitivity Tests | 7 | 2019 | 1965 | 0.320 |
Why?
|
Pyrazinamide | 3 | 2016 | 60 | 0.310 |
Why?
|
Family Health | 1 | 2013 | 1256 | 0.310 |
Why?
|
Infant | 23 | 2022 | 36497 | 0.310 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2181 | 0.310 |
Why?
|
Mass Screening | 6 | 2022 | 5455 | 0.300 |
Why?
|
Treatment Failure | 7 | 2023 | 2656 | 0.290 |
Why?
|
Child | 35 | 2022 | 80863 | 0.290 |
Why?
|
Antibiotics, Antitubercular | 3 | 2005 | 99 | 0.290 |
Why?
|
Developing Countries | 8 | 2013 | 2901 | 0.260 |
Why?
|
Electronic Health Records | 2 | 2013 | 4877 | 0.240 |
Why?
|
National Health Programs | 4 | 2021 | 442 | 0.230 |
Why?
|
Humans | 91 | 2024 | 768451 | 0.230 |
Why?
|
Tuberculin Test | 3 | 2019 | 205 | 0.230 |
Why?
|
Pakistan | 4 | 2022 | 298 | 0.210 |
Why?
|
Age Factors | 12 | 2022 | 18478 | 0.210 |
Why?
|
Primary Prevention | 2 | 2020 | 1189 | 0.210 |
Why?
|
Population Surveillance | 3 | 2011 | 2601 | 0.210 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 2005 | 367 | 0.200 |
Why?
|
Adult | 44 | 2024 | 223542 | 0.200 |
Why?
|
Ethambutol | 2 | 2016 | 59 | 0.190 |
Why?
|
Young Adult | 17 | 2024 | 60045 | 0.190 |
Why?
|
Treatment Outcome | 22 | 2023 | 65409 | 0.190 |
Why?
|
Drug Resistance, Multiple | 2 | 2001 | 255 | 0.190 |
Why?
|
Cost of Illness | 1 | 2010 | 1960 | 0.180 |
Why?
|
Female | 51 | 2024 | 396943 | 0.180 |
Why?
|
Male | 50 | 2024 | 364781 | 0.180 |
Why?
|
Internet | 1 | 2012 | 3123 | 0.170 |
Why?
|
Early Diagnosis | 2 | 2015 | 1196 | 0.170 |
Why?
|
Infant, Newborn | 10 | 2022 | 26395 | 0.170 |
Why?
|
Secondary Prevention | 3 | 2016 | 1479 | 0.170 |
Why?
|
HIV Infections | 7 | 2020 | 17564 | 0.170 |
Why?
|
Economics | 1 | 2000 | 141 | 0.160 |
Why?
|
Endemic Diseases | 1 | 2000 | 191 | 0.160 |
Why?
|
Retrospective Studies | 25 | 2021 | 81834 | 0.160 |
Why?
|
Genome, Bacterial | 1 | 2024 | 798 | 0.160 |
Why?
|
Communicable Disease Control | 3 | 2021 | 857 | 0.150 |
Why?
|
Incidence | 8 | 2019 | 21552 | 0.150 |
Why?
|
Environmental Exposure | 1 | 2013 | 4533 | 0.150 |
Why?
|
BCG Vaccine | 3 | 2014 | 383 | 0.140 |
Why?
|
Prevalence | 8 | 2020 | 15880 | 0.140 |
Why?
|
Health Services Accessibility | 5 | 2022 | 5510 | 0.140 |
Why?
|
Prospective Studies | 10 | 2021 | 54914 | 0.130 |
Why?
|
Amidohydrolases | 1 | 2016 | 160 | 0.130 |
Why?
|
Lost to Follow-Up | 1 | 2016 | 123 | 0.130 |
Why?
|
Drug Therapy, Combination | 7 | 2021 | 6320 | 0.130 |
Why?
|
Cohort Studies | 13 | 2024 | 41797 | 0.120 |
Why?
|
Entamoebiasis | 1 | 2013 | 12 | 0.110 |
Why?
|
Protozoan Infections | 1 | 2013 | 38 | 0.110 |
Why?
|
Amebiasis | 1 | 2013 | 33 | 0.110 |
Why?
|
Giardiasis | 1 | 2013 | 28 | 0.110 |
Why?
|
Blastocystis Infections | 1 | 2013 | 17 | 0.110 |
Why?
|
Genotype | 4 | 2019 | 13047 | 0.110 |
Why?
|
Drug Resistance, Bacterial | 3 | 2013 | 1064 | 0.100 |
Why?
|
Middle Aged | 21 | 2024 | 223418 | 0.100 |
Why?
|
Delivery of Health Care | 2 | 2021 | 5367 | 0.100 |
Why?
|
Sentinel Surveillance | 1 | 2014 | 292 | 0.100 |
Why?
|
Haiti | 2 | 2013 | 553 | 0.100 |
Why?
|
Disease Progression | 2 | 2019 | 13655 | 0.100 |
Why?
|
Health Policy | 2 | 2017 | 2699 | 0.100 |
Why?
|
Disease Notification | 1 | 2012 | 95 | 0.100 |
Why?
|
Electronic Prescribing | 1 | 2013 | 114 | 0.100 |
Why?
|
Analysis of Variance | 3 | 2020 | 6242 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6537 | 0.100 |
Why?
|
Comprehensive Health Care | 1 | 2012 | 123 | 0.090 |
Why?
|
Public-Private Sector Partnerships | 1 | 2012 | 123 | 0.090 |
Why?
|
Urban Health Services | 1 | 2012 | 177 | 0.090 |
Why?
|
Professional Competence | 1 | 2014 | 431 | 0.090 |
Why?
|
Likelihood Functions | 1 | 2014 | 993 | 0.090 |
Why?
|
Mutation | 4 | 2016 | 30243 | 0.090 |
Why?
|
Computer Systems | 1 | 2012 | 470 | 0.090 |
Why?
|
Socioeconomic Factors | 3 | 2022 | 7863 | 0.090 |
Why?
|
Information Systems | 1 | 2012 | 397 | 0.090 |
Why?
|
Geographic Information Systems | 1 | 2012 | 283 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2000 | 1764 | 0.090 |
Why?
|
Community Health Services | 3 | 2011 | 659 | 0.090 |
Why?
|
Time Factors | 8 | 2014 | 40271 | 0.090 |
Why?
|
Follow-Up Studies | 6 | 2019 | 39430 | 0.080 |
Why?
|
Risk Factors | 14 | 2024 | 74915 | 0.080 |
Why?
|
Registries | 2 | 2013 | 8373 | 0.080 |
Why?
|
Program Development | 2 | 2012 | 1296 | 0.080 |
Why?
|
Epidemiologic Studies | 1 | 2012 | 681 | 0.080 |
Why?
|
Risk | 3 | 2016 | 9642 | 0.080 |
Why?
|
Tobacco Smoke Pollution | 1 | 2014 | 828 | 0.080 |
Why?
|
Public Health | 1 | 2022 | 2693 | 0.080 |
Why?
|
Lesotho | 3 | 2013 | 73 | 0.080 |
Why?
|
Health Personnel | 3 | 2021 | 3384 | 0.070 |
Why?
|
Models, Organizational | 1 | 2011 | 546 | 0.070 |
Why?
|
Russia | 3 | 2014 | 386 | 0.070 |
Why?
|
Healthcare Disparities | 2 | 2022 | 3412 | 0.070 |
Why?
|
Odds Ratio | 5 | 2022 | 9687 | 0.070 |
Why?
|
HIV Seronegativity | 1 | 2008 | 211 | 0.070 |
Why?
|
Genes, Bacterial | 1 | 2011 | 1076 | 0.070 |
Why?
|
Community-Acquired Infections | 1 | 2011 | 473 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2013 | 1277 | 0.070 |
Why?
|
HIV Seropositivity | 1 | 2012 | 963 | 0.070 |
Why?
|
Cross Infection | 1 | 2015 | 1425 | 0.070 |
Why?
|
Clinical Protocols | 4 | 2021 | 1444 | 0.070 |
Why?
|
Program Evaluation | 2 | 2011 | 2508 | 0.070 |
Why?
|
Aged | 11 | 2024 | 171520 | 0.060 |
Why?
|
World Health Organization | 3 | 2020 | 1328 | 0.060 |
Why?
|
Checklist | 1 | 2012 | 843 | 0.060 |
Why?
|
Health Education | 1 | 2012 | 1059 | 0.060 |
Why?
|
Recurrence | 3 | 2016 | 8510 | 0.060 |
Why?
|
Treatment Refusal | 1 | 2008 | 432 | 0.060 |
Why?
|
Streptomycin | 1 | 2004 | 69 | 0.060 |
Why?
|
Drug Resistance, Microbial | 2 | 2005 | 830 | 0.060 |
Why?
|
Drug Administration Schedule | 4 | 2016 | 4861 | 0.060 |
Why?
|
Infection Control | 1 | 2010 | 985 | 0.050 |
Why?
|
Health Services Needs and Demand | 1 | 2011 | 1408 | 0.050 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2011 | 952 | 0.050 |
Why?
|
Case-Control Studies | 4 | 2015 | 22293 | 0.050 |
Why?
|
Tuberculin | 1 | 2022 | 64 | 0.050 |
Why?
|
Public Health Administration | 1 | 2005 | 242 | 0.050 |
Why?
|
Feeding Behavior | 1 | 2014 | 3202 | 0.050 |
Why?
|
Community Health Centers | 1 | 2005 | 470 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 4049 | 0.040 |
Why?
|
Tajikistan | 1 | 2000 | 4 | 0.040 |
Why?
|
Practice Guidelines as Topic | 2 | 2011 | 7451 | 0.040 |
Why?
|
X-Rays | 1 | 2021 | 312 | 0.040 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 12561 | 0.040 |
Why?
|
Sequence Analysis, DNA | 2 | 2016 | 4780 | 0.040 |
Why?
|
Ambulatory Care | 2 | 2008 | 2780 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 8051 | 0.040 |
Why?
|
Vulnerable Populations | 2 | 2017 | 717 | 0.040 |
Why?
|
Methicillin Resistance | 1 | 1999 | 198 | 0.040 |
Why?
|
Pregnancy | 1 | 2020 | 30179 | 0.040 |
Why?
|
Sampling Studies | 1 | 2000 | 617 | 0.040 |
Why?
|
Social Support | 1 | 2008 | 2195 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15965 | 0.040 |
Why?
|
Substance-Related Disorders | 2 | 2012 | 4453 | 0.040 |
Why?
|
Smoking | 1 | 2014 | 9099 | 0.040 |
Why?
|
Decision Making | 1 | 2011 | 3961 | 0.040 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 2019 | 478 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8559 | 0.030 |
Why?
|
International Cooperation | 1 | 2003 | 1439 | 0.030 |
Why?
|
Prognosis | 1 | 2016 | 30028 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3438 | 0.030 |
Why?
|
Gene Expression | 2 | 2019 | 7605 | 0.030 |
Why?
|
Research Design | 2 | 2013 | 6217 | 0.030 |
Why?
|
Health Resources | 1 | 2001 | 950 | 0.030 |
Why?
|
Sex Factors | 2 | 2020 | 10647 | 0.030 |
Why?
|
Entamoeba | 1 | 2013 | 5 | 0.030 |
Why?
|
Endolimax | 1 | 2013 | 6 | 0.030 |
Why?
|
Blastocystis hominis | 1 | 2013 | 6 | 0.030 |
Why?
|
Risk Assessment | 4 | 2020 | 24311 | 0.030 |
Why?
|
HIV | 1 | 2001 | 1596 | 0.030 |
Why?
|
Genetic Fitness | 1 | 2015 | 120 | 0.030 |
Why?
|
Giardia lamblia | 1 | 2013 | 23 | 0.030 |
Why?
|
Capreomycin | 1 | 2013 | 14 | 0.030 |
Why?
|
Cost-Benefit Analysis | 3 | 2021 | 5532 | 0.030 |
Why?
|
Kanamycin | 1 | 2013 | 63 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14728 | 0.030 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2013 | 33 | 0.030 |
Why?
|
Biological Assay | 1 | 2016 | 629 | 0.030 |
Why?
|
Logistic Models | 2 | 2022 | 13324 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2014 | 509 | 0.030 |
Why?
|
Clarithromycin | 1 | 2013 | 87 | 0.030 |
Why?
|
Molecular Epidemiology | 1 | 2015 | 473 | 0.030 |
Why?
|
Latvia | 1 | 2012 | 15 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2001 | 1903 | 0.030 |
Why?
|
Estonia | 1 | 2012 | 56 | 0.030 |
Why?
|
Philippines | 1 | 2012 | 95 | 0.030 |
Why?
|
HIV Seroprevalence | 1 | 2012 | 89 | 0.020 |
Why?
|
Georgia (Republic) | 1 | 2011 | 39 | 0.020 |
Why?
|
England | 1 | 2013 | 533 | 0.020 |
Why?
|
Radiography | 1 | 2022 | 6995 | 0.020 |
Why?
|
Fluoroquinolones | 1 | 2013 | 309 | 0.020 |
Why?
|
Drug Therapy | 1 | 2014 | 504 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2003 | 3708 | 0.020 |
Why?
|
Models, Theoretical | 2 | 2014 | 3590 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 2021 | 1439 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2014 | 12096 | 0.020 |
Why?
|
Health Surveys | 1 | 2000 | 4056 | 0.020 |
Why?
|
Genetic Loci | 1 | 2019 | 2630 | 0.020 |
Why?
|
Monocytes | 1 | 2019 | 2591 | 0.020 |
Why?
|
Focus Groups | 1 | 2015 | 1448 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2011 | 427 | 0.020 |
Why?
|
Financing, Personal | 1 | 2011 | 310 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2015 | 2733 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 26351 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2596 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 2932 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2012 | 941 | 0.020 |
Why?
|
Survival Rate | 1 | 2000 | 12875 | 0.020 |
Why?
|
Education | 1 | 2008 | 536 | 0.020 |
Why?
|
Consensus | 1 | 2015 | 3207 | 0.020 |
Why?
|
Retreatment | 1 | 2006 | 601 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2011 | 1514 | 0.010 |
Why?
|
Peroxidases | 1 | 2004 | 134 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2016 | 4052 | 0.010 |
Why?
|
Aged, 80 and over | 3 | 2014 | 59680 | 0.010 |
Why?
|
Motivation | 1 | 2012 | 2034 | 0.010 |
Why?
|
Oxidoreductases | 1 | 2004 | 412 | 0.010 |
Why?
|
Parents | 1 | 2015 | 3596 | 0.010 |
Why?
|
Survival Analysis | 1 | 2014 | 10125 | 0.010 |
Why?
|
Algorithms | 2 | 2012 | 14158 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2016 | 14766 | 0.010 |
Why?
|
Virulence | 1 | 2004 | 1303 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2019 | 12774 | 0.010 |
Why?
|
Patient Care Team | 1 | 2011 | 2526 | 0.010 |
Why?
|
Models, Statistical | 1 | 2014 | 5103 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2012 | 3629 | 0.010 |
Why?
|
Probability | 1 | 2004 | 2483 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2012 | 3237 | 0.010 |
Why?
|
Poverty | 2 | 2001 | 2719 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2004 | 2863 | 0.010 |
Why?
|
Health Care Costs | 1 | 2011 | 3265 | 0.010 |
Why?
|
Databases, Factual | 1 | 2013 | 8081 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10601 | 0.010 |
Why?
|
Health Planning | 1 | 1998 | 233 | 0.010 |
Why?
|
HIV-1 | 1 | 2013 | 6966 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15460 | 0.010 |
Why?
|
Morals | 1 | 1998 | 289 | 0.010 |
Why?
|
Body Mass Index | 1 | 2012 | 13030 | 0.010 |
Why?
|
Patient Compliance | 1 | 2004 | 2696 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10784 | 0.010 |
Why?
|
Rural Population | 1 | 2001 | 2317 | 0.010 |
Why?
|
Bacterial Proteins | 1 | 2004 | 3861 | 0.010 |
Why?
|
Disease Management | 1 | 1999 | 2533 | 0.000 |
Why?
|
Mental Disorders | 1 | 2008 | 6879 | 0.000 |
Why?
|
Anti-HIV Agents | 1 | 2001 | 4567 | 0.000 |
Why?
|